X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1882) 1882
Book Review (348) 348
Publication (122) 122
Newsletter (26) 26
Book Chapter (13) 13
Conference Proceeding (7) 7
Magazine Article (6) 6
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1413) 1413
humans (1349) 1349
hydroxychloroquine (1249) 1249
female (862) 862
hydroxychloroquine - therapeutic use (661) 661
male (644) 644
adult (562) 562
rheumatology (516) 516
middle aged (498) 498
systemic lupus erythematosus (427) 427
lupus (353) 353
chloroquine (283) 283
lupus erythematosus, systemic - drug therapy (263) 263
aged (262) 262
antirheumatic agents - therapeutic use (254) 254
treatment outcome (253) 253
rheumatoid arthritis (202) 202
risk factors (199) 199
arthritis, rheumatoid - drug therapy (195) 195
hydroxychloroquine - administration & dosage (188) 188
hydroxychloroquine - adverse effects (187) 187
abridged index medicus (186) 186
rheumatoid-arthritis (185) 185
animals (173) 173
drug therapy, combination (173) 173
methotrexate (171) 171
care and treatment (169) 169
patients (168) 168
therapy (161) 161
adolescent (151) 151
immunology (150) 150
disease (149) 149
dermatology (148) 148
lupus erythematosus, systemic - complications (148) 148
medicine & public health (147) 147
arthritis (144) 144
pregnancy (142) 142
pharmacology & pharmacy (137) 137
drug therapy (135) 135
health aspects (135) 135
hydroxychloroquine - pharmacology (134) 134
systemic-lupus-erythematosus (133) 133
analysis (128) 128
research (123) 123
diagnosis (118) 118
young adult (114) 114
retrospective studies (108) 108
inflammation (106) 106
immunosuppressive agents - therapeutic use (104) 104
antirheumatic agents - adverse effects (99) 99
child (96) 96
corticosteroids (96) 96
medicine, general & internal (95) 95
severity of illness index (95) 95
antimalarials - therapeutic use (92) 92
antiphospholipid syndrome (91) 91
methotrexate - therapeutic use (91) 91
autophagy (90) 90
time factors (89) 89
drugs (86) 86
risk-factors (85) 85
autoimmune diseases (83) 83
antibodies (82) 82
antimalarials (81) 81
classification (81) 81
diagnosis, differential (81) 81
follow-up studies (81) 81
women (81) 81
biopsy (80) 80
medical research (79) 79
internal medicine (77) 77
lupus erythematosus, systemic - blood (77) 77
risk (77) 77
antiphospholipid antibodies (76) 76
double-blind (74) 74
lupus erythematosus, systemic - diagnosis (74) 74
mice (74) 74
hydroxychloroquine - blood (71) 71
inhibition (71) 71
dosage and administration (70) 70
toxicity (70) 70
prevalence (69) 69
prospective studies (69) 69
article (68) 68
nephritis (68) 68
dose-response relationship, drug (67) 67
prednisone - therapeutic use (67) 67
rheumatoid factor (67) 67
glucocorticoids - therapeutic use (66) 66
thrombosis (66) 66
cancer (65) 65
antirheumatic agents - administration & dosage (64) 64
chloroquine - therapeutic use (64) 64
lupus erythematosus, systemic - immunology (64) 64
aged, 80 and over (63) 63
autoantibodies (62) 62
disease-activity (62) 62
management (62) 62
ophthalmology (62) 62
prednisone (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1859) 1859
French (29) 29
German (9) 9
Spanish (7) 7
Italian (5) 5
Chinese (4) 4
Korean (3) 3
Finnish (2) 2
Danish (1) 1
Japanese (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Romanian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Arthritis & Rheumatology, ISSN 2326-5191, 05/2017, Volume 69, Issue 5, pp. 953 - 963
Objective. To investigate whether the Multi-Biomarker Disease Activity (MBDA) score predicts optimal add-on treatment in patients with early rheumatoid... 
RADIOGRAPHIC PROGRESSION | HYDROXYCHLOROQUINE | 3 MEDICATIONS | SULFASALAZINE | VALIDATION | RHEUMATOLOGY | SWEFOT TRIAL | CONVENTIONAL COMBINATION TREATMENT | COLLEGE-OF-RHEUMATOLOGY | 2-YEAR | ACR/EULAR REMISSION CRITERIA | Hydroxychloroquine - therapeutic use | Blood Sedimentation | Arthritis, Rheumatoid - blood | Humans | Male | Methotrexate - therapeutic use | Infliximab - therapeutic use | C-Reactive Protein - metabolism | Leptin - blood | Arthritis, Rheumatoid - drug therapy | Interleukin-6 - blood | Treatment Failure | Chitinase-3-Like Protein 1 - blood | Female | Drug Therapy, Combination | Antirheumatic Agents - therapeutic use | Resistin | Severity of Illness Index | Sulfasalazine - therapeutic use | Receptors, Tumor Necrosis Factor, Type I - blood | Serum Amyloid A Protein - metabolism | Decision Support Techniques | Vascular Endothelial Growth Factor A - blood | Treatment Outcome | Biomarkers - blood | Epidermal Growth Factor - blood | Randomized Controlled Trials as Topic | Vascular Cell Adhesion Molecule-1 - blood | Matrix Metalloproteinase 1 - blood | Matrix Metalloproteinase 3 - blood | Therapy | Categories | infliximab | Medical services | Data processing | Arthritis | Pharmacology | Inflammation | Tumor necrosis factor-α | Digital divide | E.S.R | Sedimentation | Patients | Randomization | Hydroxychloroquine | Rheumatoid arthritis | Monoclonal antibodies | Biomarkers | Sulfasalazine | Bioindicators | Methotrexate | Index Medicus | Abridged Index Medicus | Rheumatoid Arthritis | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Reumatologi och inflammation
Journal Article
BioMed Research International, ISSN 2314-6133, 2019, Volume 2019, pp. 2437105 - 8
Objectives. This study aims to correlate subclinical echocardiographic features with the clinical, laboratory, and therapeutic profiles of the patients to... 
CRITERIA | MEDICINE, RESEARCH & EXPERIMENTAL | DENSITY-LIPOPROTEIN CHOLESTEROL | RISK-FACTORS | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ATHEROSCLEROSIS | CLASSIFICATION | MITRAL REGURGITATION | PREVALENCE | CORONARY-ARTERY-DISEASE | Heart Valve Diseases - blood | Blood Sedimentation | Lupus Erythematosus, Systemic - complications | Lipoproteins, HDL - blood | Cholesterol - blood | Humans | Middle Aged | Hypertension, Pulmonary - physiopathology | Lupus Erythematosus, Systemic - metabolism | Male | Metabolic Syndrome - metabolism | Lupus Erythematosus, Systemic - blood | Hypertension, Pulmonary - blood | Metabolic Syndrome - blood | Heart Valve Diseases - complications | Echocardiography, Doppler | Metabolic Syndrome - physiopathology | Mitral Valve Insufficiency - complications | Adult | Female | Uric Acid - blood | Pericardial Effusion - complications | Heart - physiopathology | Heart Valve Diseases - physiopathology | Pericardial Effusion - blood | Pericardial Effusion - physiopathology | Metabolic Syndrome - complications | Blood Cell Count | Heart - diagnostic imaging | Heart Valve Diseases - metabolism | Triglycerides - blood | Lupus Erythematosus, Systemic - physiopathology | Mitral Valve Insufficiency - blood | Mitral Valve Insufficiency - physiopathology | Lipoproteins, LDL - blood | Hypertension, Pulmonary - complications | Mitral Valve Insufficiency - metabolism | Corticoids | Laboratories | Anthropometry | Mucosa | Cardiovascular disease | Metabolic syndrome | Risk factors | Necrosis | Demographics | Systemic lupus erythematosus | Regurgitation | Atherosclerosis | Aorta | Blood pressure | Lesions | Heart diseases | Age | Thickening | Lupus | Hypertension | Avascular necrosis | Urine | Phenotypes | Immunoglobulins | Echocardiography | Corticosteroids | Leukopenia | Effusion | Pulmonary arteries | Rheumatology | Triglycerides | Patients | Coronary artery disease | Cholesterol | Laboratory tests | Chronic conditions | Lipoproteins | Hydroxychloroquine | Correlation analysis | Ulcers | Health risk assessment | Females | Autoimmune diseases | Metabolic disorders | Index Medicus
Journal Article
Lupus, ISSN 0961-2033, 7/2012, Volume 21, Issue 8, pp. 830 - 835
Objective: We sought to determine the effect of hydroxychloroquine therapy on the levels proinflammatory/prothrombotic markers and disease activity scores in... 
Lupus | biomarkers of inflammation | hydroxychloroquine | biomarkers of thrombosis | SYSTEMIC-LUPUS-ERYTHEMATOSUS | RISK-FACTORS | ANTICARDIOLIPIN ANTIBODIES | ANTIPHOSPHOLIPID ANTIBODIES | RHEUMATOLOGY | ANTIMALARIAL-DRUGS | INTERFERON-ALPHA | ENDOTHELIAL-CELLS | TNF-ALPHA | 3 ETHNIC-GROUPS | T-CELLS | Hydroxychloroquine - therapeutic use | Interleukin-1beta - drug effects | Interferon-alpha - drug effects | United States | CD40 Ligand - blood | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Interleukin-8 - drug effects | Male | Lupus Erythematosus, Systemic - blood | Interleukin-1beta - blood | Young Adult | Chemokine CXCL10 - drug effects | Interleukin-6 - blood | Lupus Erythematosus, Systemic - ethnology | Lupus Erythematosus, Systemic - drug therapy | Statistics, Nonparametric | Adult | Female | Antirheumatic Agents - pharmacology | Interleukin-8 - blood | Antirheumatic Agents - therapeutic use | Cytokines - blood | Severity of Illness Index | Chemokine CXCL10 - blood | Biomarkers - blood | Chemokine CCL2 - blood | CD40 Ligand - drug effects | Tumor Necrosis Factor-alpha - drug effects | Cytokines - drug effects | Interferon-alpha - blood | Adolescent | Hydroxychloroquine - pharmacology | Chemokine CCL2 - drug effects | Cohort Studies | CD40 antigen | Cytokines | Antibodies | Data processing | Inflammation | cardiolipin | Interleukin 6 | Hydroxychloroquine | Systemic lupus erythematosus | IP-10 protein | alpha -Interferon | Enzyme-linked immunosorbent assay | Immunoassays | Interleukin 8 | Monocyte chemoattractant protein 1 | Tumor necrosis factor- alpha | Index Medicus
Journal Article
Journal Article
by Jallouli, M and Galicier, L and Zahr, N and Aumaître, O and Francès, C and Le Guern, V and Lioté, F and Smail, A and Limal, N and Perard, L and Desmurs‐Clavel, H and Le Thi Huong, D and Asli, B and Kahn, J.‐E and Pourrat, J and Sailler, L and Ackermann, F and Papo, T and Sacré, K and Fain, O and Stirnemann, J and Cacoub, P and Leroux, G and Cohen‐Bittan, J and Sellam, J and Mariette, X and Blanchet, B and Hulot, J. S and Amoura, Z and Piette, J. C and Costedoat‐Chalumeau, N and Astudillo, Leonardo and Belizna, Cristina and Belmatoug, Nadia and Benveniste, Olivier and Benyamine, Audrey and Bezanahary, Holly and Blanco, Patrick and Bletry, Olivier and Bodaghi, Bahram and Bourgeois, Pierre and Brihaye, Benoît and Chatelus, Emmanuel and Damade, Richard and Daugas, Eric and De‐Gennes, Christian and Delfraissy, Jean‐François and Delluc, Céline and Delluc, Aurélien and Duhaut, Pierre and Dupuy, Alain and Durieu, Isabelle and Ea, Hang‐Korng and Farge, Dominique and Funck‐Brentano, Christian and Gandjbakhch, Frédérique and Gellen‐Dautremer, Justine and Ghillani‐Dalbin, Pascale and Godeau, Bertrand and Goujard, Cécile and Grandpeix, Catherine and Grange, Claire and Grimaldi, Lamiae and Guettrot, Gaëlle and Guillevin, Loïc and Hachulla, Eric and Harle, Jean‐Robert and Haroche, Julien and Hausfater, Pierre and Jouquan, Jean and Kaplanski, Gilles and Keshtmand, Homa and Khellaf, Mehdi and Lambotte, Olivier and Launay, David and Lechat, Philippe and Levesque, Hervé and Lidove, Olivier and Liozon, Eric and Ly, Kim and Mahevas, Matthieu and Mariampillai, Kubéraka and Mathian, Alexis and Mazodier, Karin and Michel, Marc and Morel, Nathalie and Mouthon, Luc and Musset, Lucile and Ngack, Rokiya and Ninet, Jacques and Oksenhendler, Eric and Pellegrin, Jean‐Luc and Peyr, Olivier and Piette, Anne‐Marie and Poindron, Vincent and Roux, Fabienne and Saadoun, David and Sahali, Sabrinel and Saint‐Marcoux, Bernadette and Sarrot‐Reynauld, Françoise and ... and Plaquenil Lupus Systemic Study Grp and Plaquenil Lupus Systemic Study Group
Arthritis & Rheumatology, ISSN 2326-5191, 08/2015, Volume 67, Issue 8, pp. 2176 - 2184
Journal Article
Journal Article
Journal Article